To date, seven randomized trials have evaluated the efficacy of expedited partner treatment (EPT). These trials have included heterosexual men and women and examine EPT for Chlamydia trachomatis, Neisseria gonorrhoea, and Trichomonas vaginalis. These studies demonstrated either superiority for percentage of partners being treated, for a reduction in repeat infections, or cost benefit for EPT compared to the standard partner referral method and reported no adverse events. In the United States, although the number of states where EPT is legal continues to grow, adoption of EPT remains low. Provider concerns about liability and payment issues continue to be a barrier to implementation of EPT. More translational research is needed to improve adoption by the players involved: index patients, partners, providers, and payers.